Study summary · Dogs · Joint and mobility · 2006
A promising improvement signal, with mixed clinical results
More dogs improved with the tested extract after eight weeks, but the overall clinical-score comparison did not reach the usual statistical threshold.
Why this study matters
“More dogs improved” and “a larger average improvement” answer different questions. Reading both helps owners judge how convincing a supplement claim is.
How the study worked
Participants
84 dogs entered; 81 were analysed after three exclusions. Clinical-score analysis used 70 complete datasets.
What happened?
SF4 Dog green-lipped mussel extract tablets, given by body-weight group for 56 days; all dogs then received extract for 56 days.
The comparison
Matched placebo during the first 56 days only.
What was measured?
Veterinary examination scores, proportion improving, owner assessments and laboratory tolerance checks.
What the researchers found
| Outcome | Reported result | How to read it |
|---|---|---|
| Dogs improving at day 56 | 67% versus 41%; P=.018 | About 26 percentage points more with extract. |
| Cumulative clinical score | Between-group P=.053 | Did not meet the .05 threshold. |
| Tolerance | No attributable adverse effects identified | Does not establish rare or long-term safety. |
What strengthens the evidence?
Random allocation, double blinding and a placebo comparison reduce several sources of bias.
What limits the conclusions?
Incomplete data, subjective assessments, a short controlled phase and one formulation limit confidence and generalisability. The later open-label phase cannot separate treatment effects from expectations.
What the researchers concluded
The authors considered the tested extract beneficial and well tolerated, with improvement potentially taking eight weeks or longer.
Evidence.pet interpretation
This trial supports further investigation of the specific preparation. It does not establish that every mussel powder, extract or food containing mussel has the same effect. A statistically significant difference in the proportion improving does not tell us how large or meaningful each dog’s improvement was. An overall score with P=.053 should not be described as statistically significant at the .05 threshold. A joint-care decision should consider the total evidence and the individual dog, rather than treating one positive outcome as a guarantee.
Funding and author interests
McFarlane Laboratories NZ Ltd, the product supplier, provided financial support.
Read the original research
Pollard B, Guilford WG, Ankenbauer-Perkins KL, Hedderley D. Clinical efficacy and tolerance of an extract of green-lipped mussel (Perna canaliculus) in dogs presumptively diagnosed with degenerative joint disease. New Zealand Veterinary Journal. 2006;54(3):114–118. doi:10.1080/00480169.2006.36622.
Ingredient context: Green-lipped mussel. Read how preparations differ and what to look for on a product label.
Evidence.pet editorial summary · Study ID STU-019 · Source checked 23 September 2026. Strengths, limitations and interpretation are our editorial assessment, not a formal evidence grade.
Full-text editorial appraisal completed 23 September 2026. This is a critical reading of one trial, not a systematic review or formal certainty grade.